Join the club for FREE to access the whole archive and other member benefits.

SENISCA targets sensescence using a new ageing hallmark - dysregulated mRNA processing

Lorna Harries believes dysregulated splicing as a breakthrough senotherapeutic target

03-Nov-2021

Key points from article :

Lorna Harries, the CSO and R&D lead at SENISCA Ltd, announced dysregulated mRNA processing as a new hallmark of aging

Restoration of splicing factor expression results in reversal of multiple aspects of cellular senescence.

Senostatic approach aims not to remove senescent cells but rather to stop their pathogenic features.

Computational chemistry approach to identify compounds for use in the aesthetic aging sector.

Oligonucleotides can be used in tiny doses and delivered to specific tissues or even cell types very specifically.

Currently optimizing novel oligonucleotides to maximize effect...will be moving through IND submission.

We’re just making the cells do what younger cells do naturally.

FOXO proteins have so many roles in the cell, – in our case, to target splicing regulation.

At the current time, healthspan extension is our focus.

We’re poised at the threshold of a whole new way of holistically treating age-related diseases, and I’m excited to be part of it.

Mentioned in this article:

Click on resource name for more details.

Lorna Harries

Professor of Molecular Genetics at the University of Exeter

SENISCA

University of Exeter spinout developing senotherapeutic interventions through modulation of dysregulated RNA splicing

Topics mentioned on this page:
Ageing Research, Senescent Cells